Stock Analiz

AIM ImmunoTech Inc. AIM

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$0.14Market cap $6M
Open the interactive analysis →

AIM ImmunoTech Inc. (AIM) is a healthcare company listed in the US with a market value of about $6M. In the twelve months to September 30, 2026 it had revenue of $91000 and net income of -$14M, a net margin of -15526.4%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -12% a year, a 5-year average ROIC of -258%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About AIM ImmunoTech

AIM ImmunoTech is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $197000 in 2014 to $88000 in 2025, a decline of about 7.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 237% over three years (dilution for shareholders). It spends 4459% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S63.0
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)-48.2%
Revenue growth (5 yrs, per year)-11.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-13669.2%
ROIC (5-yr avg.)-258.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$91000$88000$170000$202000$141000$135000$163000$140000$367000$437000$92000
Net income-$14M-$14M-$17M-$29M-$19M-$19M-$14M-$9M-$10M-$8M-$8M
Free cash flow——-$15M—-$16M-$14M-$10M-$9M-$11M-$8M-$8M
EPS (diluted)$-0.35$-0.34$-1.24$-2.40$-1.60$-1.60$-1.80$-10.32$-39.08$-51.04$-59.84
Net margin-15526.4%-15861.4%-10188.2%-14337.6%-13790.8%-14168.1%-8834.4%-6717.1%-2677.7%-1889.9%-8154.3%
ROIC——-737.1%-230.2%-40.0%-26.1%-18.8%-61.7%-112.2%-85.6%-70.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $4.25, 2860% above the current price; targets range from $1.50 to $7.00; the consensus rating is “none”; expected EPS is $-0.78 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is AIM ImmunoTech stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does AIM ImmunoTech pay a dividend?

Not currently.

Is AIM ImmunoTech a good stock to buy?

We do not give buy or sell advice. AIM ImmunoTech scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.